Tags : 5 years


Eli Lilly Reports Results of Taltz (ixekizumab) in 5 Years

Shots: The P-III study results involves assessing of Taltz in patients with moderate to severe plaque psoriasis for 5yrs.in addition to an extension study UNCOVER-1 Collective results: 90%+ maintained skin clearance as measured by PASI 75; @264wks. PASI 75 (94.3); PASI 90 (81.8%); PASI 100 (46.6%), presented at WCD with additional data of UNCOVER-3 study […]Read More


Abbott India Plans to Launch 100 products in next 5

Shots:  The focus is to expand existing therapy areas and strengthen over-the-counter portfolio worldwide with range of products making QoL better The US based subsidiary has already launched 21 new products in last financial year 2017 Abbott India markets over 110 brands in multiple therapeutic areas including women’s health, thyroid, pain management, general care, vitamins […]Read More